we are an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. our name, 2seventy bio, is inspired by the maximum speed of translating human thought into action—270 miles per hour, and at 2seventy, we think in the language of time. with a deep understanding of cancer cell metabolism, genomics, and the human body’s immune response to tumor cells, we’re applying this knowledge and expertise to new classes of cellular therapies that are designed to “think” smarter and faster than cancer. it is this mindset that propels us forward because we know that time matters -- every day, every minute, every second -- to people living with cancer
Company profile
Ticker
TSVT
Exchange
Website
CEO
Nick Leschly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
2seventy bio Securities Corporation ...
IRS number
863658454
TSVT stock data
Latest filings (excl ownership)
8-K
Other Events
9 Apr 24
8-K
Regulation FD Disclosure
5 Apr 24
8-K/A
Financial Statements and Exhibits
1 Apr 24
8-K
Completion of Acquisition or Disposition of Assets
1 Apr 24
DEFA14A
Additional proxy soliciting materials
20 Mar 24
8-K
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
20 Mar 24
8-K
Departure of Directors or Certain Officers
18 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
13 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 92.14 mm | 92.14 mm | 92.14 mm | 92.14 mm | 92.14 mm | 92.14 mm |
Cash burn (monthly) | 1.84 mm | 3.00 mm | 25.99 mm | 17.07 mm | 7.17 mm | 13.32 mm |
Cash used (since last report) | 12.58 mm | 20.48 mm | 177.31 mm | 116.48 mm | 48.92 mm | 90.88 mm |
Cash remaining | 79.55 mm | 71.66 mm | -85.17 mm | -24.35 mm | 43.21 mm | 1.26 mm |
Runway (months of cash) | 43.1 | 23.9 | -3.3 | -1.4 | 6.0 | 0.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 141 |
Opened positions | 26 |
Closed positions | 28 |
Increased positions | 52 |
Reduced positions | 28 |
13F shares | Current |
---|---|
Total value | 214.16 bn |
Total shares | 54.80 mm |
Total puts | 23.10 k |
Total calls | 7.25 k |
Total put/call ratio | 3.2 |
Largest owners | Shares | Value |
---|---|---|
Kynam Capital Management | 5.95 mm | $23.34 bn |
BLK Blackrock | 4.42 mm | $17.31 bn |
Vanguard | 3.73 mm | $14.64 bn |
Millennium Management | 3.65 mm | $14.30 bn |
Newtyn Management | 3.08 mm | $12.06 bn |
Wellington Management | 2.99 mm | $11.74 bn |
Baker Bros. Advisors | 2.50 mm | $9.79 bn |
Casdin Capital | 2.02 mm | $7.93 bn |
Point72 Asset Management | 1.66 mm | $6.51 bn |
Madison Avenue Partners | 1.49 mm | $5.86 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | William D Baird III | Common Stock | Grant | Acquire A | No | No | 0 | 56,250 | 0.00 | 308,585 |
1 Apr 24 | William D Baird III | Stock Options Common Stock | Grant | Acquire A | No | No | 5.79 | 112,500 | 651.38 k | 112,500 |
1 Apr 24 | Victoria Eatwell | Common Stock | Grant | Acquire A | No | No | 0 | 42,500 | 0.00 | 96,647 |
1 Apr 24 | Victoria Eatwell | Stock Options Common Stock | Grant | Acquire A | No | No | 5.79 | 85,000 | 492.15 k | 85,000 |
1 Apr 24 | Jessica Snow | Common Stock | Grant | Acquire A | No | No | 0 | 31,250 | 0.00 | 56,286 |
1 Apr 24 | Jessica Snow | Stock Options Common Stock | Grant | Acquire A | No | No | 5.79 | 62,500 | 361.88 k | 62,500 |
News
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
19 Apr 24
Citigroup Maintains Buy on 2seventy bio, Raises Price Target to $12
8 Apr 24
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
5 Apr 24
U.S. FDA Approves Bristol Myers Squibb And 2seventy bio's Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy; Abecma Tripled Progression-Free Survival Compared To Standard Regimens In The Phase 3 KarMMa-3 trial, With A 51% Reduction In Risk Of Disease Progression Or Death And A Well-Established Safety Profile
5 Apr 24
2seventy bio Adds Eli Casdin And Charles Newton To Board
20 Mar 24
Press releases
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
5 Apr 24
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
20 Mar 24
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
15 Mar 24
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
1 Mar 24
2seventy bio to Participate in Upcoming Investor Conferences
5 Feb 24